The administration of anti-PD-1 antibody to mice with treated with METTL3-knockdown M2 macrophages led to a more significant delay in tumor growth compared to those receiving anti-PD-1 antibody with control M2 macrophages (Fig. 7O-P). Here, METTL3 is linked to neoplasm.